Plasma Osteoprotegerin and Cognitive Impairment after Ischemic Stroke.

Current neurovascular research Pub Date : 2025-01-29 DOI:10.2174/0115672026368528250113080256

Xinyue Chang, Pinni Yang, Yi Liu, Yu He, Xiaoli Qin, Beiping Song, Quan Yu, Jiawen Fei, Mengyao Shi, Daoxia Guo, Yanbo Peng, Jing Chen, Aili Wang, Tan Xu, Jiang He, Yonghong Zhang, Zhengbao Zhu

{"title":"Plasma Osteoprotegerin and Cognitive Impairment after Ischemic Stroke.","authors":"Xinyue Chang, Pinni Yang, Yi Liu, Yu He, Xiaoli Qin, Beiping Song, Quan Yu, Jiawen Fei, Mengyao Shi, Daoxia Guo, Yanbo Peng, Jing Chen, Aili Wang, Tan Xu, Jiang He, Yonghong Zhang, Zhengbao Zhu","doi":"10.2174/0115672026368528250113080256","DOIUrl":null,"url":null,"abstract":"Background: Plasma osteoprotegerin (OPG) has been linked to poor prognosis following stroke, but its impact on post-stroke cognitive impairment (PSCI) is unknown. The purpose of our work was to analyze the relationship of OPG with PSCI.Methods: Our study included 613 ischemic stroke subjects with plasma OPG levels. We used the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) to assess PSCI. PSCI was defined as MMSE score <25 or MoCA score <23.Results: As assessed by the MMSE score, the adjusted odds ratio for PSCI in the highest OPG tertile was 1.77, with a 95% confidence interval of 1.09 to 2.89 (Ptrend=0.021), compared to that in the lowest tertile. We observed a positive linear relationship of plasma OPG levels with 3- month PSCI (P for linearity=0.046). Incorporating plasma OPG into conventional risk factors enhanced PSCI risk reclassification (all P <0.05). Consistent results were discovered when PSCI was evaluated using the MoCA score.Conclusion: High plasma OPG levels were related to an elevated risk of 3-month PSCI, indicating that OPG might be an effective biomarker for predicting PSCI.","PeriodicalId":93965,"journal":{"name":"Current neurovascular research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current neurovascular research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672026368528250113080256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Plasma osteoprotegerin (OPG) has been linked to poor prognosis following stroke, but its impact on post-stroke cognitive impairment (PSCI) is unknown. The purpose of our work was to analyze the relationship of OPG with PSCI.

Methods: Our study included 613 ischemic stroke subjects with plasma OPG levels. We used the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) to assess PSCI. PSCI was defined as MMSE score <25 or MoCA score <23.

Results: As assessed by the MMSE score, the adjusted odds ratio for PSCI in the highest OPG tertile was 1.77, with a 95% confidence interval of 1.09 to 2.89 (Ptrend=0.021), compared to that in the lowest tertile. We observed a positive linear relationship of plasma OPG levels with 3- month PSCI (P for linearity=0.046). Incorporating plasma OPG into conventional risk factors enhanced PSCI risk reclassification (all P <0.05). Consistent results were discovered when PSCI was evaluated using the MoCA score.

Conclusion: High plasma OPG levels were related to an elevated risk of 3-month PSCI, indicating that OPG might be an effective biomarker for predicting PSCI.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Current neurovascular research

自引率

0.00%

发文量